Mersana Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Mersana Therapeutics details its 2024 financial results and provides updates on its clinical programs, including Emi-Le and XMT-2056.
10-K: Mersana Therapeutics Bolsters Leadership with Strategic Hire and Outlines Executive Compensation
Mersana Therapeutics appoints a new SVP, Strategic Product Planning & Program Leadership, and details compensation policies for non-employee directors.